European Wound Management Association

MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

Retrieved on: 
Thursday, March 21, 2024
Burn, Tax, Debridement, Patient, EWMA, Bank statement, Eschar, Investment, SAWC, Therapy, Depreciation, European Commission, Phase, BCC, Research, Supplement, Wound, EMA, GMP, HERE, Safety, CMS, BLA, Eastern Time Zone, Food, Bromelain (pharmacology), WBP, Development, PMI, WHS, Adjustment, FDA, BMCI, Forecasting, Symposium, Incidence, BSV, Basal-cell carcinoma, Operating cost, European Wound Management Association, Table, Event, Medicare, Pharmaceutical industry

YAVNE, Israel, March 21, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • Revenue: Revenue for the fourth quarter 2023 was $5.3 million, compared to $11.6 million in the fourth quarter of 2022.
  • Research and development expenses in the fourth quarter 2023 were $1.8 million compared to $2.7 million in the fourth quarter of 2022.
  • Selling, general, and administrative expenses in the fourth quarter 2023 were $2.8 million, compared to $3.0 million in the fourth quarter of 2022.
  • Operating Results: Operating loss in the fourth quarter of 2023 was $3.9 million, compared to an operating profit of $2.1 million in the fourth quarter of 2022.

MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study

Retrieved on: 
Monday, February 12, 2024
Incidence, FDA, EWMA, Safety, Debridement, Wound, WBP, Patient, Symposium, WHS, Granulation tissue, Disease, SAWC, NSS, European Wound Management Association, Wound healing

SANTYL is currently the market-leading enzymatic debridement product, with more than $360 million in estimated annual sales in the United States.

Key Points: 
  • SANTYL is currently the market-leading enzymatic debridement product, with more than $360 million in estimated annual sales in the United States.
  • Ofer Gonen, CEO of MediWound said, “These head-to-head results position EscharEx to become the market leader in enzymatic agents for the treatment of chronic wounds.
  • All are achieved within a short time frame to facilitate early wound closure, a major benefit for patients suffering from chronic non-healing wounds.
  • The incidence of achieving WBP throughout the study was 78.3% (95% CI = 63.6-89.1) for EscharEx vs. 37.5% for SANTYL (95% CI=8.5-75.5); p=0.03.

UK Leads European Medical Tapes & Wraps Market with 21% Share, Driven by Rising Chronic Diseases - ResearchAndMarkets.com

Retrieved on: 
Monday, November 6, 2023
Hospitals, Health, Medical Supplies, Ulcer, Trauma, Prevalence, Conditional sentence, Diabetes, Hospital, Accident, Cancer, European Wound Management Association, Medical device

The European medical tapes & wraps market is poised for substantial growth, with an expected CAGR of 3.64%, reaching $3.46 billion by 2028 from $2.79 billion in 2022.

Key Points: 
  • The European medical tapes & wraps market is poised for substantial growth, with an expected CAGR of 3.64%, reaching $3.46 billion by 2028 from $2.79 billion in 2022.
  • This market analysis report provides comprehensive insights into the European medical tapes & wraps market, covering market size, forecasts, segmentations, and industry trends.
  • UK Dominance: In 2022, the UK emerged as the market leader, accounting for over 21.00% of the European market share.
  • The European medical tapes & wraps market features a wide array of prominent vendors, including:

FeelTect receives top prize at European Wound Management Association (EWMA) Innovation Forum for Tight Alright connected health solution

Retrieved on: 
Tuesday, June 13, 2023
Quality of life, EWMA, Doctor of Philosophy, European Wound Management Association, MD, Patient, Physician, Mouth ulcer, Self-management, Wound healing, Medical device

GALWAY, Ireland, June 13, 2023 /PRNewswire/ -- FEELTECT, a connected-health, wound care company, was recently awarded first place in the annual innovation competition as part of the European Wound Management Association (EWMA) Innovation Forum.

Key Points: 
  • GALWAY, Ireland, June 13, 2023 /PRNewswire/ -- FEELTECT, a connected-health, wound care company, was recently awarded first place in the annual innovation competition as part of the European Wound Management Association (EWMA) Innovation Forum.
  • The EWMA Innovation Forum was held as part of the annual EWMA conference, which this year took place in Milan, Italy.
  • The innovation competition recognises pioneering innovations that address critical unmet needs in wound care.
  • Based on the judges' preliminary evaluations, a shortlist of 16 start-up companies from across Europe were invited to present at the Innovation Forum event.

FeelTect receives top prize at European Wound Management Association (EWMA) Innovation Forum for Tight Alright connected health solution

Retrieved on: 
Tuesday, June 13, 2023
Quality of life, EWMA, Doctor of Philosophy, European Wound Management Association, MD, Patient, Physician, Mouth ulcer, Self-management, Wound healing, Medical device

GALWAY, Ireland, June 13, 2023 /PRNewswire/ -- FEELTECT, a connected-health, wound care company, was recently awarded first place in the annual innovation competition as part of the European Wound Management Association (EWMA) Innovation Forum.

Key Points: 
  • GALWAY, Ireland, June 13, 2023 /PRNewswire/ -- FEELTECT, a connected-health, wound care company, was recently awarded first place in the annual innovation competition as part of the European Wound Management Association (EWMA) Innovation Forum.
  • The EWMA Innovation Forum was held as part of the annual EWMA conference, which this year took place in Milan, Italy.
  • The innovation competition recognises pioneering innovations that address critical unmet needs in wound care.
  • Based on the judges' preliminary evaluations, a shortlist of 16 start-up companies from across Europe were invited to present at the Innovation Forum event.

Kane Biotech Announces FDA 510(k) Clearance for its coactiv+™ Antimicrobial Wound Gel

Retrieved on: 
Thursday, May 25, 2023
Wound, Failure, Amputation, SAWC, Leg, EWMA, Sepsis, European Wound Management Association, Medicare, Disinfectant, KNE, Diabetic foot, Symposium, Coactivator (genetics), Bacteria, Ulcer, Burns, FDA, Death, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Pharmaceutical industry

“FDA clearance of our coactiv+ Antimicrobial Wound Gel, is a major milestone for Kane,” said Marc Edwards, President and Chief Executive Officer.

Key Points: 
  • “FDA clearance of our coactiv+ Antimicrobial Wound Gel, is a major milestone for Kane,” said Marc Edwards, President and Chief Executive Officer.
  • “We’re bringing an effective, differentiated, and accessible product to the annual USD $200 million1 U.S. antimicrobial wound hydrogel market.
  • More information about Kane’s coactiv+ Antimicrobial Wound Gel can be found at www.coactivplus.com.
  • coactiv+ Antimicrobial Hydrogel will significantly increase the ability of healthcare clinicians to effectively treat chronic wounds and burns.

MolecuLight Featured in Unprecedented 24 Presentations and Posters at European Wound Management Association (EWMA) 2023 Annual Conference

Retrieved on: 
Wednesday, May 3, 2023
ZINC, Infection, University, SKIN, RCT, EWMA, European Wound Management Association, Medical director, Collection, DX, Accuracy and precision, Genetically modified bacteria, Conference, FDA, Health Canada, Wound healing, Medical imaging, Nursing, Medical device

TORONTO and MILAN, May 3, 2023 /PRNewswire/ - MolecuLight Inc ., the leader in point-of-care fluorescence imaging that detects and locates elevated bacterial loads in wounds, announces that its MolecuLight wound imaging platform is featured in an unprecedented 24 presentations and posters at the European Wound Management Association (EWMA) 2023 Annual Conference , being hosted from May 3 - 5, 2023 in Milan, Italy.

Key Points: 
  • TORONTO and MILAN, May 3, 2023 /PRNewswire/ - MolecuLight Inc ., the leader in point-of-care fluorescence imaging that detects and locates elevated bacterial loads in wounds, announces that its MolecuLight wound imaging platform is featured in an unprecedented 24 presentations and posters at the European Wound Management Association (EWMA) 2023 Annual Conference , being hosted from May 3 - 5, 2023 in Milan, Italy.
  • Held annually, EWMA is the largest wound care conference in Europe and one of the largest events globally for wound care professionals.
  • "The impressive collection of 24 talks and posters from so many facilities globally shows how the MolecuLight imaging device is becoming a new standard-of-care in wound care.
  • "There are tangible clinical benefits for using the MolecuLight alongside a broad range of wound care procedures, in all wound care settings.

MolecuLight Featured in Unprecedented 24 Presentations and Posters at European Wound Management Association (EWMA) 2023 Annual Conference

Retrieved on: 
Wednesday, May 3, 2023
ZINC, Infection, University, SKIN, RCT, EWMA, European Wound Management Association, Medical director, Collection, DX, Accuracy and precision, Genetically modified bacteria, Conference, FDA, Health Canada, Wound healing, Medical imaging, Nursing, Medical device

TORONTO and MILAN, May 3, 2023 /PRNewswire/ -- MolecuLight Inc., the leader in point-of-care fluorescence imaging that detects and locates elevated bacterial loads in wounds, announces that its MolecuLight wound imaging platform is featured in an unprecedented 24 presentations and posters at the European Wound Management Association (EWMA) 2023 Annual Conference, being hosted from May 3 - 5, 2023 in Milan, Italy. Held annually, EWMA is the largest wound care conference in Europe and one of the largest events globally for wound care professionals.

Key Points: 
  • TORONTO and MILAN, May 3, 2023 /PRNewswire/ -- MolecuLight Inc ., the leader in point-of-care fluorescence imaging that detects and locates elevated bacterial loads in wounds, announces that its MolecuLight wound imaging platform is featured in an unprecedented 24 presentations and posters at the European Wound Management Association (EWMA) 2023 Annual Conference , being hosted from May 3 - 5, 2023 in Milan, Italy.
  • Held annually, EWMA is the largest wound care conference in Europe and one of the largest events globally for wound care professionals.
  • "The impressive collection of 24 talks and posters from so many facilities globally shows how the MolecuLight imaging device is becoming a new standard-of-care in wound care.
  • "There are tangible clinical benefits for using the MolecuLight alongside a broad range of wound care procedures, in all wound care settings.

Daniel Kraft set to address SAWC Spring | WHS | DLS, the world's leading wound care meeting, with keynote on convergent trends covering personal genomics to robotics

Retrieved on: 
Tuesday, March 28, 2023
CWSP, Chin Na, Abstract, Communication, Partnership, CWS, Education, WCPC, Health, SAWC, Face, Marketing, European Wound Management Association, Therapy, American Physical Therapy Association, Research, DLS, Regenerative medicine, WHS, MD, Patient, Physician, Learning, Faculty, Robotics, Conference, National Harbor, Maryland, Nursing, Medical device

MALVERN, Pa., March 28, 2023 /PRNewswire-PRWeb/ -- Visionary physician and innovator Daniel Kraft, MD will deliver a keynote presentation highlighting rapidly emerging, game-changing, and convergent healthcare technology trends at the 2023 Symposium on Advanced Wound Care (SAWC) Spring | Wound Healing Society (WHS), co-located with the Diabetic Limb Salvage (DLS) Conference.

Key Points: 
  • Now in its 36th year, SAWC Spring | WHS | DLS will be held April 26-30 in National Harbor, Maryland, providing the latest education on the prevention and management of wound care and scientific excellence.
  • The educational agenda features an expert faculty lineup, depth of discussions, and exposure to innovation, evidence-based practices, and techniques.
  • "Through his research and practice, he will provide a window into the future for wound care professionals and for patients.
  • Learning tracks encompass the business of wound care as well as separate tracks through DLS and WHS.

DGAP-News: Debrichem / NHS: Significant cost-effectiveness and better outcomes in VLUs, as published in Journal of Wound Care

Retrieved on: 
Monday, June 13, 2022
European Wound Management Association, Infection, Time, Amputation, Company, Health status of White Americans, Anesthetic, SC, Risk factor, Ulcer, Venous insufficiency, Diabetic neuropathy, Health care, CEO, Moyamoya disease, Vasculitis, NHS, Bandage, Female, Probability, EWMA, Maintenance, Dr. med. Sommer II, Patient, Disease, Hospital, Diabetes, COVID-19, National Health Service, Incidence, Quality of life, Diagnosis, Prevalence, Obesity, Cytokine, Overalls, Protein, Mouth ulcer, Venous ulcer, Wound healing, Markov, Medicine, Medical device, Health insurance, Pharmaceutical industry, VLU

Debrichem / NHS: Significant cost-effectiveness and better outcomes in VLUs, as published in Journal of Wound Care

Key Points: 
  • Debrichem / NHS: Significant cost-effectiveness and better outcomes in VLUs, as published in Journal of Wound Care
    The issuer is solely responsible for the content of this announcement.
  • In total, the NHS could save up to 57% on wound care management costs in treating hard-to-heal VLUs.
  • DEBx Medical aims to support doctors and their patients from diagnosis through treatment, follow-up care and maintenance of a healthy wound bed.
  • DEBx Medical is commercializing Debrichem through a worldwide network covering more than 50 countries, with the first market launches e.g.